Minerva replaces CEO Vivaldi; Eleven Bio raises $20M; Vyrix punts IPO;

@FierceBiotech: Cell Medica hauls in $78M to get its #cancer immunotherapy through Phase II. Story | Follow @FierceBiotech

@JohnCFierce: Trending - UPDATED: J&J jumps into hot CAR-T field with gene-editing experts at Transposagen. Article | Follow @JohnCFierce

@DamianFierce: $BMRN + $RNA sub-question: Does drisapersen qualify for a future rare pediatric disease voucher? | Follow @DamianFierce

> Minerva Neurosciences says that CEO Rogerio Vivaldi is leaving the company at the end of this month by "mutual agreement." He is being replaced by Remy Luthringer, president and chief scientific officer of Minerva. Release

> Eleven Biotherapeutics has raised $20 million in fresh financing through a private placement. The biotech says it plans to use the money for R&D, with Phase III data on a dry eye disease drug expected in Q2 2015. Release

> Vyrix Pharmaceuticals has withdrawn its IPO, citing market conditions. Story

Medical Device News

@FierceMedDev: Reva raises $25M to get CE mark for bioresorbable scaffold. Article | Follow @FierceMedDev

@VarunSaxena2: Updated with more information from Bloomberg: Stryker said to be interested in buying Smith & Nephew (once again). More | Follow @VarunSaxena2

@EmilyWFierce: $BSX sinks some funds into an Iowa-based startup developing an ablation device for atrial fibrillation. Story | Follow @EmilyWFierce

> Researchers develop 'Wi-Fi'-triggered dissolvable, implantable device for drug delivery. Story

> Covidien gets 510(k) for peripheral balloon catheter aimed at hemodialysis patients. More

Pharma News

@FiercePharma: U.K. gatekeepers toughest on cancer meds--and getting tougher all the time. More | Follow @FiercePharma

@CarlyHFierce: Lundbeck CEO exits in disgrace, endangering key new launches. Story | Follow @CarlyHFierce

> Which Allergan execs will stay? Actavis won't say, but promises job cuts, China growth. Article

> Novo Nordisk shrinks executive team as top-ranking woman leaves. More

> Takeda's U.S. chief bows out amid management shake-up. Report

Biotech Research News

> Autoimmune experts discover a new pathway for multiple sclerosis R&D. Story

> U.K.'s MRC outlicenses Parkinson's discovery program to China's Yabao. More

> Nanotech team mounts a search-and-destroy mission against cancer cells. Article

> UC Irvine investigators spotlight a new class of 'chemosensitizers.' News

> Rodent studies point to a new target for ovarian cancer R&D. Story

Pharma Manufacturing News

> Merck KGaA to power India plant with coconut and cashew shells. More

> AbbVie buys API plant in Singapore where it's already building one. News

> Baxter labeling issue could leave patients short on potassium chloride. Story

> Merck manufacturing know-how brought to bear on NewLink Ebola vaccine. Item

> AstraZeneca joins Bristol-Myers, Amgen in biologics buildup. Article

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.